Figure 3.

Progression-free time of melanoma patients with different CTC alterations after treatment. The progression-free time of each melanoma patients was used to conduct survival analysis. (A) Patients with low CTC level had longer progression-free survival than patients with high CTC level (P value: 0.014). (B) Patients with increased CTC level after the treatment showed worse survival than patients with decreased CTC level or unchanged CTC level. P value was 0.012. (The patients who withdrew from this study, were lost from the follow-up, or survived to the endpoint of the follow-up were defined as censored cases).